CSF3 and congenital rubella syndrome: In addition, we speculated that maybe an improved cytoreduction prior to CAR T–cell therapy could lower the BM leukemic burden, hence reducing the risk of G-CSF-induced CRS and NE, which makes G-CSF easier to use when indicated in severely neutropenic patients.